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 M1 (iNOS) and M2 (CD163 , ARG-1) markers of microglia polarization were investigated in 
GBM tumors and in the surrounding parenchyma from the same patients 
 CD163 expression was higher within GBM specimens than in surrounding periphery in both 
male and female patients, and was inversely correlated with mean survival times. 
 A prevailing iNOS-like profile was present within the tumor, at variance with the peripheral 
parenchyma surrounding the tumor.  
 No significant association was found between ARG-1 or iNOS expression and survival time. 
 
 
 
 
 
ABSTRACT 
 
Microglia and macrophages appear to be the most common cells in the GBM microenvironment. In the 
present study we investigated the status of macrophages/microglia activation in surgical specimens from 
41 patients diagnosed with grade IV GBM. For each patient we analyzed both the center of tumor and the 
parenchyma surrounding the tumor. The specimens were stained for: i) IBA1, a 17-kDa EF hand protein 
specifically expressed in microglia/macrophages ii) CD163, a cell surface antigen associated with M2 
phenotype; iii) iNOS, taken as a functional marker of M1 phenotype, and iv) ARG-I, taken as a functional 
marker of M2 phenotype. Staining was scored in a double-blinded score on a scale from 0 to 5. Our results 
suggest that CD163 expression is higher within the tumor than in surrounding periphery in both male and 
female patients; while iNOS is higher within the tumor in males, no significant difference was found for 
ARG-1. In addition, analyzing the data in TGCA database, we found that CD163 expression was significantly 
and inversely correlated with mean survival times, with average survival times ranging from 448 days in 
patients having low expression, to 319 in mid, and 353 in patients with high CD163 expressing tumors. In 
contrast, no significant association was found between survival time and ARG-1 or iNOS expression. 
 
Keywords: Glioblastoma, microglia, M1 polarization, M2 polarization, tumor, periphery, iNOS, 
ARG-I, CD163. 
 
 
INTRODUCTION 
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Glioblastoma (GBM) is the most frequent and lethal primary brain tumor in adults, representing 
15% of all brain tumors [1]. Epidemiological data show an estimated incidence of 2–3 GBM cases 
per 100 000 adults in Europe and North America each year; the incidence rate in men compared to 
women is 1.26/1 [2]. Despite surgical resection, radiotherapy and chemotherapy, the average 
survival of GBM patients is 14-16 months, and the 5-year survival rate is 3.3% [3]. Given the poor 
results of current therapeutic strategies, which are mainly directed against GBM cells, other 
cellular types (vascular cells, microglia, peripheral immune cells, and neural precursor cells) within 
the CNS might be envisioned as targets for the development of novel additional therapeutic 
options. Among these cells, tumor-associated resident microglia and macrophages appear to be 
the most common cells in the GBM microenvironment [4; 5; 6]. Studies of glioma specimens 
revealed that GBM contains a higher number of infiltrating macrophages compared to lower grade 
gliomas [7]. More recently, the activation status rather than the abundance of glioma-associated 
microglia/macrophages present in the tumor microenvironment has been suggested to have 
prognostic value [8; 9].  
 
Similar to peripheral macrophages, microglia can acquire an activated M1 phenotype, 
characterized by the ability to release pro-inflammatory cytokines/mediators such as IL-1β, IL-6, 
TNF-α, CCL2, reactive oxygen species (ROS), and nitric oxide (NO) [10; 11]. Additionally, or 
alternatively, microglia can express an M2 phenotype, which is associated with the ability to 
produce anti-inflammatory and immune suppressive factors, including ARG-1, Ym1, and CD36, as 
well as to up-regulate the cell surface markers CD163, CD204 and CD206 and the anti-
inflammatory cytokines, such as IL-10 [12]. Recently, M0 microglia (also referred to as resting 
microglia) have also been reported; M0 microglia are considered to possess an attenuated M2 
phenotype. In healthy brain, M0 microglia show intrinsic properties contributing to the 
maintenance of a healthy environment for neuronal function [13]. Glioma associated 
microglia/macrophages (GAM) were found to express both M1/M2 polarization markers in human 
GBM specimens [14; 15; 16]. Looking at GAM profile, Gabrusiewicz and collaborators showed that 
a continuum exists between the M1 and M2 like phenotypes; in the apparent difficulty to 
distinguish between M1 and M2 phenotypes, these authors concluded that glioblastoma-
infiltrated innate immune cells resemble M0 phenotype [17]. 
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We have previously investigated the interaction between rat microglia and rat C6 glioma cells [18; 
19]. Exposure to conditioned media obtained from C6 cells taken under baseline conditions 
induced a predominant M2-like phenotype in rat microglia. Conversely, if C6 cells were exposed to 
a medium containing pro-inflammatory agents, the subsequent exposure of microglia to such 
medium was followed by a shift toward a M1-like phenotype [18]. We interpreted these findings 
as the result of a positive-loop feed-back occurring between microglia and tumor cells: the 
exposure to inflammatory mediators causes tumor cells to release factor(s) able to shift the 
polarization state of microglia towards a M1 profile [18]. 
 
In the present work, we used tissue specimens of GBM obtained from the Neurosurgery Unit of 
the Catholic University Medical School to study microglia/macrophage polarization in GBM 
pathology. The surgical samples typically included at least 1-2 cm of peripheral parenchyma 
surrounding the tumor, hence we were able to compare the polarization status of 
microglia/macrophages within the tumor with that of microglia/macrophages localized in the 
peripheral parenchyma in each sample, allowing us to identify putative changes in polarization 
profile, possibly related with the proximity to tumor cells. 
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Methods  
Patients and Specimens 
We enrolled 41 adults mean age 58.5 (34-79), 27 males/14 females, that were operated for 
primary GBM at our Neurosurgery Department, from March 2005 to September 2011. We 
selected this group because in all cases a total tumor removal was achieved, allowing us to obtain 
tissues samples from both the tumor and the surrounding macroscopic normal brain tissue 
(between 1 cm and 2 cm from the tumor border; larger resections were performed in tumors that 
grew far from eloquent areas) [20; 21; 22]. All patients provided written consent to use their 
specimens for research purposes; none of them was identifiable. The local ethics committee 
(Catholic University Ethics Committee, Rome) approved the study. The ethical principles of the 
declaration of Helsinki were strictly followed.  
 
Tissue preparation and immunohistochemistry 
Human tumor tissue obtained from surgical resection of patients with grade IV GBM were fixed in 
4% paraformaldehyde in 0.1 M phosphate buffer pH 7.6 overnight at 4°C. Dehydration of tissue 
was through a series of 80%, 95% ethanol one hour each followed by 100% ethanol overnight. Two 
100% xylene washes were done for 1h each and then 1h in 60°C Paraplast Plus (Tyco/Healthcare, 
Mansfield, MA). After a change of Paraplast Plus, tissue was incubated in a 60°C vacuum oven for 
2h prior to placing in molds to cool and solidify. Sections, 3-4 μm thick, were cut and mounted. 
Sections were deparaffinized by drying on superfrost plus slides (Fisher), heating at 56°C 
overnight, and then washing through mixed xylenes, 100% ethanol, 95% ethanol, ddH2O. Slides 
were immersed in 10 mM citrate buffer, pH 6.0, dry heated for 10 min each to unmask antigen 
sites, and then cooled and washed in PBS. Endogenous peroxidase activity was inhibited by rinsing 
the slides in 3% hydrogen peroxide for 5 min. Nonspecific binding was blocked by 5 min incubation 
with the Super Block Solution (ScyTek Laboratories, Utah, USA). After washing in PBS, sections 
were incubated for 30 minutes at room temperature with, Rabbit Anti-Human Arginase-1 
Polyclonal Antibody (Spring Bioscience) 1:75, Rabbit Anti-Human CD163 Polyclonal Antibody 
(Spring Bioscience) 1:200, with Rabbit Anti-Human iNOS Polyclonal Antibody (Spring Bioscience) 
1:75 or over-night with Goat Anti-Human Iba1 polyclonal antibody (Novus Biologicals) 1:250. The 
conditions of staining have been standardized in control tissues, using normal human lung as a 
control for iNOS and IBA1, and human hepato-carcinoma as a control for ARG-1. Sections were 
washed extensively with PBS and subsequently treated with the Ultra Tek Anti-Polyvalent kit 
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(ScyTek Laboratories). Finally sections were treated with 3,3’-diaminobenzidine as chromogen, 
contrasted with Hematoxylin and mounted [19].  
 
Analysis 
Staining of human specimens was evaluated by two examiners who were blinded as to the 
antibody used. Staining was scored on a scale from 0 to 5. In particular, score 0 indicates no 
significant staining, score 1 very low staining, score 2 low staining, score 3 significant staining, 
score 4 high staining and score 5 indicates very high staining. Figure 1 shows representative 
pictures for each antibody and score. Statistical comparisons between the average intensity of 
staining were made by non-parametric unpaired T-test. Correlations between staining scores were 
determined using non-parametric Spearman test. Chi-square test was used for the analysis of Δ 
data. Differences were taken as statistically significant if p < 0.05.  
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Results 
Forty-one sections of glioma tissue obtained from surgical resection of patients diagnosed with 
grade IV GBM were stained for: i) IBA-1, a 17-kDa EF hand protein that is specifically expressed in 
microglia/macrophages ii) CD163, a cell surface antigen associated with M2 phenotype; iii) iNOS, 
taken as a functional marker of M1 phenotype, and iv) ARG-I, taken as a functional marker of M2 
phenotype. For each patient we analyzed both the center of the tumor (T) and the parenchyma at 
the periphery of tumor (P), the latter defined as the tissue distant by at least 1-2 cm from the 
tumor border.  
 
All specimens were positive for IBA-1. The intensity score for all the specimens was 4 or 5, with no 
difference either between tumor versus parenchyma or between female vs male gender. A 
representative field for the tumor and a representative field for the peripheral parenchyma, both 
scored 5 for IBA-1, are shown in figures 2A and 2B respectively. While the intensity of IBA-1 
staining was similar between tumor and surrounding parenchyma, we observed a difference in 
microglia/macrophages morphology between the two areas, with a prevalence of amoeboid 
morphology within the tumor (Fig 2A) compared to a prevalence of resting morphology at the 
periphery (Fig 2B). 
 
All specimens were positive for CD163 in both the tumor (T) and the parenchyma (P) (Table 1). In 
particular, 17% (6/41) of cases showed an intensity score in T equal to the intensity score in P, 
whereas 71% (30/41) of patients showed a higher intensity score in T compared to the periphery 
and only 12% (5/41) of patients showed a CD163 intensity score lower in the tumor compared to 
the periphery (Fig 3). Differently three tumor specimens and 6 cases of peripheral tissue were 
found negative for iNOS staining, with one case (#17) being negative in both T and P (Table 1). 
Looking at the individual cases, 22% (9/41) of cases showed an intensity score in T equal to the 
intensity score in P, whereas 66% (27/41) of patients showed a higher intensity score in T 
compared to the periphery; only 12% (5/41) of patients showed an iNOS intensity score lower in 
the tumor compared to the periphery (Fig 3). Finally four tumor specimens and 3 peripheral 
parenchyma specimens were found negative (score 0) for ARG-I staining, although these did not 
overlap. (Table 1). There were 34% (14/41) of cases showing an intensity score in T equal to the 
intensity score in P, whereas 46% (19/41) of patients showed a higher intensity score in T 
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compared to the periphery and only 20% (8/41) of patients showed an ARG-I intensity score lower 
in the tumor compared to the periphery (Fig 3).  
 
Comparing the average intensity scores of our markers for the combined male plus female groups 
in T and P respectively (data expressed as the means ± SEM of 41 replicates per group), significant 
differences were found for both iNOS and CD163 (Fig 4). In the case of iNOS, the intensity score 
within the tumors was 2.46±0.21 versus 1.56±0.16 in the peripheral tissue. Likewise, the intensity 
score for CD163 staining was significantly higher within the tumors compared to the peripheral 
parenchyma: 3.32±0.18 versus 2.39±0.16. The difference between T and P staining for CD163 was 
also present in the individual male and female groups, whereas the difference for iNOS staining 
was present in the male, but not in the female group (Fig 4). In addition staining for CD163 in P 
was significantly greater in males than females. On the contrary, we found no significant 
difference between tumor and peripheral ARG-I staining in any of the groups (Fig 4).  
 
Not only it was relevant to show if there was any difference between marker expression in T 
versus P, but also to estimate the extent of such difference; having defined Δ as the difference 
between the iNOS and the ARG1 scores within the tumor (or in periphery) in each patient, or else 
as the difference between the iNOS and the CD163 scores within the tumor (or in periphery) in 
each patient, we looked at the rate of cases with Δ higher than 2 over the total of cases. In the 
periphery, 80% of the cases showed the same intensity score for iNOS and ARG-I, 10% of cases 
showed a higher Δ score for iNOS than ARG-I, and 10% of the cases showed a higher Δ score for 
ARG-I than iNOS (Fig 5A). Conversely in the tumors, we found a slightly lower number of cases 
(71%) showing the same intensity score for iNOS and ARG-I, and a marked, statistically significant 
prevalence of cases showing a higher Δ score for iNOS than ARG-I (22% of cases compared to 7% 
of cases with higher ARG-I Δ score) (Fig 5B).  
 
The cross-analysis between CD163 and iNOS was somewhat less straightforward, and provided 
slightly different results compared to the iNOS-ARG-I comparison, mostly because we were 
comparing an inducible protein towards a surface antigen expressed in a constitutive manner by 
microglial cells. Nevertheless, in this case as well we found a statistically significant shift toward a 
M1 profile by moving from the periphery to the tumor, with a net 5% increase in cases were iNOS 
was prevalent compared to CD163 by a factor >2 (Fig 5C-D).  
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To determine if these expression patterns are associated with GBM survival, we interrogated the 
TCGA database [https://genome-cancer.ucsc.edu/proj/site/hgHeatmap/] (Fig 6). CD163 expression 
was significantly and inversely correlated with mean survival times, reducing average survival from 
448 days in patients having low expression, to 319 in mid, and 353 in patients with high CD163 
expressing tumors. In contrast, associations between survival time and Arg1 or iNOS expression 
did not reach statistical significance.  
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DISCUSSION 
In the present study, we investigated the status of microglia/macrophages activation in surgical 
specimens from 41 patients diagnosed with IV grade GBM. For each patient we analyzed both the 
center of tumor and the parenchyma surrounding the tumor. In particular, we focused on the 
presence of microglia/macrophages cells both in tumor mass and in parenchyma surrounding the 
tumor, because microglia/macrophages may serve as a potential and additional target in GBM 
therapy. Regarding the parenchyma surrounding tumor, it is worth of note that neo-angiogenesis 
also occurs in the GBM peritumoral compartment [23]. Other factors correlated with the median 
patient survival time, pJNK and nestin have also been described in peritumoral tissue [24]. In 
addition, a recent paper suggests the occurrence of early tumorigenic events in GBM-neighboring 
tissue, as well as the involvement of cancer stem cells residing in the peritumoral niche in the GBM 
radio- and chemo-resistance [25].  
 
Four different markers, namely IBA-1, CD163, iNOS and ARG-I, were investigated. Ionized calcium 
binding adaptor molecule 1 [IBA-1] is a 17 kDa EF hand protein whose expression is restricted to 
microglia/macrophages. IBA-1 is a key molecule in regulating membrane ruffling and phagocytosis; 
it is involved in the signaling pathways of calcium and Rho family small GTPase, as well as of Rac, 
which plays an essential role in regulating actin reorganization in membrane ruffling [26]. 
Expression of IBA-1 is up-regulated in activated microglia in several brain diseases [26]. Based on 
this evidence, in the present study we investigated the expression of IBA-1 in our samples, 
postulating changes in gene expression associated to the presence of GBM. However, we found 
that no significant difference in IBA-1 intensity score between tumor and periphery were found 
(Fig 2).  
 
CD163 is a member of the scavenger receptor cysteine-rich (SRCR) family class B, and is expressed 
on most subpopulations of macrophages. CD163 has essentially a homeostatic activity; its best 
characterized function is the binding of Hemoglobin:Haptoglobin complexes [27]. In normal 
human CNS, CD163 is expressed by perivascular macrophages, but not by resident microglia [28]. 
However, under pathologic conditions both microglia and macrophages express CD163 [29; 30]. In 
addition, it has been suggested that CD163 positive cells or the soluble form of CD163 may play a 
role in inflammation processes, since they are found in high numbers in inflamed tissue [31]. 
CD163 has been recently associated to M2 polarization of microglia/macrophage. In particular, 
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CD163 was considered as a marker of M2a and M2c polarization status [32; 13]. A significant 
increase in CD163+ macrophages was observed in infiltrative gliomas [33]; in addition, CD163 
expression was found to be elevated in high-grade gliomas with respect the low grade glioma [34]. 
In the present work, we show that CD163 expression is higher within GBM specimens than in 
surrounding periphery in both male and female patients. (Fig 4).  
 
While CD163 data presented here show important findings, certain pitfalls concerning CD163 as a 
M2 marker should be taken into account when discussing our findings. In fact, Heusinkveld and 
van der Burg [35] reported that macrophage activation may result in a loss of expression of M2 
markers (CD163, CD16), implying that the use antibodies against CD 163 only might be insufficient 
to fully demonstrate macrophage polarization toward the M2 type. These authors also suggested 
that the study of ‘functional’ markers of the M1/M2 phenotype (such as iNOS or ARG-1, as in the 
present study) might prove useful to overcome limitations associated to the use of CD163 alone.   
 
iNOS and ARG-I give rise to two mediators, nitric oxide (NO) and ornithine respectively, that are 
involved in two opposite activities, pro-inflammatory (M1) versus anti-inflammatory function (M2) 
[36]. We were interested in these specific pathways because the enzymes both utilize L-arginine as 
substrate, and down regulate each other. The interplay between iNOS and ARG-I pathways is 
complex; in murine macrophages, ARG negatively regulates NOS activity by reducing the 
availability of L-Arg [37]. On the other hand, Nω-hydroxy-L-arginine, an intermediate in the 
synthesis of NO [38], is a competitive inhibitor of ARG [39]. Here we report that both iNOS (M1 
marker) and ARG-1 (M2 markers) are present both within the tumor and in peripheral 
parenchyma, albeit unevenly distributed. Accordingly, gene expression analysis of GBM centers 
and peritumor areas reveals that RNA molecules are differentially expressed in tumor centers vs 
their respective peritumor areas [40].  
 
Is there any correlation between iNOS, CD163 or ARG-I and patient survival? Unfortunately, our 
dataset was incomplete for the latter parameter, since many patients undergoing surgery in our 
center were followed up elsewhere; therefore, our data were largely insufficient to draw any 
statistical analysis. However, some indication might raise from the analysis of database available at 
the TCGA (The Cancer Genome Atlas) portal for survival in GMB [https://genome-
cancer.ucsc.edu/proj/site/hgHeatmap/]. Clinical information, genomic characterization data and high 
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level sequence analysis of tumor genomes are freely available at this site. For GBM, a total of 528 
cases were available at the last update on March 7, 2016. One hundred and 65 cases out of 528 
had data available for ARG-I, iNOS, CD163 gene expression, along with the relevant clinical 
histories. We carried out an analysis of these data dividing the cases (combining both male and 
female patients) into 3 groups based on gene expression levels. We found that survival was 
positively associated to lower CD163 expression levels, with the mean survival time increased to 
448 days compared to 319 days in the middle group, and 353 in the high expressing group. We 
also observed an almost significant association (P= 0.0535) between increased survival time and 
lower ARG-I levels, with mean survival time increasing to 431 days versus 366 in the mid, and 324 
days in the high expressing groups. We did not detect a significant relationship between survival 
time and iNOS expression (figure 6).  
 
Finally, we would like to point out that, while the classification of macrophages or microglial cells 
into the M1 or M2 polarized state is a well-established approach in most preclinical models, the 
same is not true in the clinical research setting, because of a high-degree of diversity and plasticity 
shown by these cell types in human pathology. There is not a clear distinction between these 
phenotypes in many disorders. Cells within the tumor often display a complex pattern of 
phenotypes, up-regulating both M1 and M2 molecular markers, and the prevalence of one 
phenotype on the other might also depend on the stage of disease [16]. In light of such apparent 
difficulty in applying the M1/M2 paradigm to the CNS, it has been convincingly postulated that the 
notion of stimulus-dependent microglia phenotype should substitute that of microglia polarization 
[41, 42].  
 
In conclusion, our data show that GBM influences microglia polarization, with a trend towards a 
iNOS-like profile respect to the periphery around the tumor. Additional studies are needed to fully 
elucidate the functional role of microglia within the glioma and see whether different microglia/ 
macrophage populations differentiate over time, and if a correlation exists between these changes 
and the outcome of disease, however M2 markers (CD163 marker) rather than M1 markers could 
be envisioned as prognostic marker. It is also possible to postulate that pharmacological strategies 
aimed at modulating microglial differentiation and modifying their polarization might have 
beneficial therapeutic effects. 
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Figure legends. 
Figure 1. Description of ICH scoring criteria. Fig 1 shows representative image for the different 
scores. The figure is dived for antibody: first line of pictures show the staining for ARG-1, the 
second line for iNOS and the last line for CD163.  Magnitude 25x. 
 
Figure 2. IBA-1 staining in human GBM specimens. A) Panel A shows a representative positive 
IBA-1 tumor field with score 5. B) Panel B shows a representative positive IBA-1 parenchyma field 
with score 5. 
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Figure 3. A) CD163, B) iNOS and C) ARG-I staining in human GBM specimens. Panel shows the 
number of cases where intensity score in T is equal to the intensity score in P (black column), 
where patients showed a higher intensity score in T compared to the periphery (blue column) and 
where patients showed an intensity score lower in the tumor compared to the periphery (red 
column) for each antibody. 
 
Figure 4. A comparison of staining for CD163, ARG-I and iNOS markers stratified by gender. The 
data were expressed as the means ± SEM of 41, 15 and 26 replicates for the male+female, female 
and male groups, respectively. Comparisons between tumor and periphery, and between female 
and male subgroups were carried out. Differences were taken as statistically significant if p < 0.05.   
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Figure 5. A comparison of staining for different markers. Figure 5 show differences between T 
and P looking at the rate of Δ for each patient higher than 2 over the total for the combined male 
and females groups. In order to carry out a chi-square test, results were re-arranged by dividing 
data into just 2 categories: iNOS>M2 marker versus iNOS ≤ M2 marker for CD163 and ARG-I. A-B) p 
= 0.00235; C-D) p = 0.002. 
 
Figure 6. Correlation between activation markers and survival. Data from TCGA for GBM samples 
was examined for correlations between survival time and gene expression levels for (A) CD163, (B) 
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ARG-I, and (C) iNOS. A total of 165 samples (male and female combined) were divided into three 
equal groups representing low (blue lines, n=55), mid (black lines, n=55), and high (red lines, n=55) 
expression. Kaplan Meier curves were generated to test for correlation by Log-rank (Mantel-Cox) 
test. There was a significant (P= 0.0152) relationship between lower CD163 expression and 
increased survival; and a trend (P= 0.0535) towards reduced survival and high ARG-I expression. 
There was no relationship between iNOS expression and survival. Average survival times for each 
group are given in the figures.  
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Table 1. Intensity score for staining of glioma tissue obtained from surgical resection of patients 
diagnosed with IV grade glioblastoma (GMB) stained for CD163, iNOS and ARG-1. 
 ARG-1 iNOS CD163 
Males 
(26/41) T P T P T P 
 Intensity score 
1 1 1 4 3 4 3 
2 3 4 4 3 2 4 
3 3 1 4 1 4 2 
6 3 0 2 1 3 3 
7 5 2 5 3 5 4 
8 1 0 2 1 5 2 
9 1 1 5 2 4 3 
10 1 1 3 2 4 3 
11 1 1 2 2 4 2 
13 0 1 3 3 4 3 
17 0 1 0 0 3 2 
19 1 1 3 1 4 2 
20 2 1 2 1 1 5 
22 4 1 4 1 5 5 
24 1 1 2 1 3 1 
25 3 1 3 2 2 3 
27 3 2 2 2 4 2 
29 2 2 2 1 3 3 
30 0 5 2 2 2 1 
31 1 1 1 2 4 3 
32 1 5 2 1 5 2 
34 1 1 2 1 3 3 
38 4 1 2 0 4 2 
39 1 1 1 1 2 1 
40 5 3 5 4 5 3 
41 2 2 4 4 4 3 
 
 
 
 
 ARG-1 iNOS CD163 
Females 
(15/41) T P T P T P 
 Intensity score 
4 2 1 2 1 3 2 
5 1 0 4 1 4 2 
12 3 1 3 2 3 2 
14 1 1 2 3 3 2 
15 4 3 0 0 1 1 
16 3 1 1 0 2 1 
18 0 3 1 0 1 2 
21 1 3 1 2 4 2 
23 1 1 0 1 3 1 
26 1 1 1 2 4 4 
28 1 3 3 2 3 2 
33 2 1 2 2 3 2 
35 3 2 3 0 3 1 
36 4 1 3 1 5 1 
37 
4 1 4 2 1 
3 
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